Prologue is designing powerful new medicines by unlocking the viral proteome. The company's state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/17/24 | $50,000,000 |
Flagship Pioneering | undisclosed |
